Do clinically insignificant tumors of the prostate exist?

Urologia Internationalis

Volumn 81, Issue 4, 2008, Pages 379-382

  Stamatiou, K ^a,b,c,d   Alevizos, A ^b,c   Mariolis, A ^c   Spiliopoulou, C ^c   Alevizou, A ^c   Bovis, K ^b   Sofras, F ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NONE   (Greece)

Author keywords

Autopsy; Prostate cancer, clinical significance; Prostate specific antigen

Indexed keywords

ARTICLE; AUTOPSY; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; INCIDENTAL FINDING; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; BIOPSY; CARCINOMA; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 57649119961     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167832     Document Type: Article

References (24)

1. Johnstone PA, Rossi PJ, Jani AB, Master V: 'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer Prostatic Dis 2007;10:237-241.
2. Konety BR, Bird VY, Deorah S, Dahmoush L: Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005;174:1785-1788.
3. Goto Y, Ohori M, Arakawa A: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
4. Billis A: Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 1986;28:324-329.
5. Guileyardo J, Johnson W, Welsh R, Akazaki K, Correa P: Prevalence of latent prostatic carcinoma in two US populations. J Natl Cancer Inst 1980;65:311-316.
6. Nicolò G, Salvi S, Musso C, d'Amore E: Latent carcinoma of the prostate. Autopsy study of 100 cases (in Italian). Pathologica 1986;78:579-591.
7. Schütze U: Latent prostatic carcinoma - an autopsy study of men over 50 years of age (in German). Zentralbl Allg Pathol 1984;129:357-364.
8. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(suppl):933-938.
9. Miyake H, Sakai I, Harada K, Hara I, Eto H: Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Int J Urol 2005;12:270-274.
10. Whittemore AS, Keller JB, Betensky R: Lowgrade, latent prostate cancer volume: predictor of clinical cancer incidence? Natl Cancer Inst 1991;83:1231-1235.
11. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998;52:444-449.
12. Brawn PN, Kuhl D, Speights VO, Johnson CF 3rd, Lind M: The incidence of unsuspected metastases from clinically benign prostate glands with latent prostate carcinoma. Arch Pathol Lab Med 1995;119:731-733.
13. Konety BR, Bird VY, Deorah S, Dahmoush L: Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005;174:1785-1788.
14. Etzioni R, Penson D, Legler J, Di Tommaso D, Boer R, Gann P, Feuer E: Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-990.
15. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S, Gill H: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998;160:2412-2417.
16. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-2040.
17. Merrill RM, Wiggins GL: Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 2002;7:213-219.
18. Baron JC, Zerbib M, Leveque JM, Deslignieres S, Boccon-Gibod L, Debre B, Steg A: Detection of a prostatic adenocarcinoma in the cysto-prostatectomy specimens of an invasive tumor of the bladder. Ann Urol 1989;23:119-122.
19. Pritchett TR, Moreno G, Warner NE: Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 1988;189:1214-1216.
20. Montie JE, Wood DP Jr, Pontes GE: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989;63:381-385.
21. Karakukis N: Latent carcinoma of the prostate; PhD thesis, University of Athens, 1990.
22. Stamey T: The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004;94:963-970.
23. Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ: Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006;175:902-906.
24. Epstein JI, Sanderson H, Carter HB, Scharfstein DO: Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005;66:356-360.